{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:14:54Z","timestamp":1792790094285,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81660427"],"award-info":[{"award-number":["81660427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation Project of Xinjiang Autonomous Region","award":["2021D01A47"],"award-info":[{"award-number":["2021D01A47"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80579-9","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T15:57:55Z","timestamp":1732377475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expression of variant isoforms of the tyrosine kinase SYK differentially regulates cervical cancer progression through PI3K\/AKT pathway"],"prefix":"10.1038","volume":"14","author":[{"given":"Bingjie","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"issue":"1","key":"80579_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73 (1), 17\u201348. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"80579_CR2","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.3802\/jgo.2016.27.e43","volume":"27","author":"H Li","year":"2016","unstructured":"Li, H., Wu, X. & Cheng, X. Advances in diagnosis and treatment of metastatic cervical cancer. J. Gynecol. Oncol. 27 (4), e43. https:\/\/doi.org\/10.3802\/jgo.2016.27.e43 (2016).","journal-title":"J. Gynecol. Oncol."},{"key":"80579_CR3","doi-asserted-by":"publisher","first-page":"107168","DOI":"10.1016\/j.intimp.2020.107168","volume":"90","author":"Y Shao","year":"2021","unstructured":"Shao, Y., Zhang, S., Zhang, Y. & Liu, Z. Recent advance of spleen tyrosine kinase in diseases and drugs. Int. Immunopharmacol. 90, 107168. https:\/\/doi.org\/10.1016\/j.intimp.2020.107168 (2021).","journal-title":"Int. Immunopharmacol."},{"issue":"6797","key":"80579_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/35021086","volume":"406","author":"PJ Coopman","year":"2000","unstructured":"Coopman, P. J. et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406 (6797), 742\u2013747. https:\/\/doi.org\/10.1038\/35021086 (2000).","journal-title":"Nature"},{"issue":"6","key":"80579_CR5","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1172\/jci61380","volume":"122","author":"J Hong","year":"2012","unstructured":"Hong, J. et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J. Clin. Invest. 122 (6), 2165\u20132175. https:\/\/doi.org\/10.1172\/jci61380 (2012).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"80579_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4103\/0973-1482.154082","volume":"12","author":"P Chuanliang","year":"2016","unstructured":"Chuanliang, P. et al. Syk expression in non-small-cell lung cancer and its relation with angiogenesis. J. Cancer Res. Ther. 12 (2), 663\u2013666. https:\/\/doi.org\/10.4103\/0973-1482.154082 (2016).","journal-title":"J. Cancer Res. Ther."},{"issue":"8","key":"80579_CR7","doi-asserted-by":"publisher","first-page":"13262","DOI":"10.1002\/jcb.28600","volume":"120","author":"H Tang","year":"2019","unstructured":"Tang, H. et al. Silencing of microRNA-27a facilitates autophagy and apoptosis of melanoma cells through the activation of the SYK-dependent mTOR signaling pathway. J. Cell Biochem. 120 (8), 13262\u201313274. https:\/\/doi.org\/10.1002\/jcb.28600 (2019).","journal-title":"J. Cell Biochem."},{"issue":"1","key":"80579_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/tox.23982","volume":"39","author":"G Tan","year":"2024","unstructured":"Tan, G. et al. Spleen tyrosine kinase facilitates the progression of papillary thyroid cancer regulated by the hsa_circ_0006417\/miR-377\u20133p axis. Environ. Toxicol. 39 (1), 421\u2013434. https:\/\/doi.org\/10.1002\/tox.23982 (2024).","journal-title":"Environ. Toxicol."},{"issue":"4","key":"80579_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00432-019-02856-9","volume":"145","author":"S Zhang","year":"2019","unstructured":"Zhang, S., Deen, S., Storr, S. J., Yao, A. & Martin, S. G. Expression of Syk and MAP4 proteins in ovarian cancer. J. Cancer Res. Clin. Oncol. 145 (4), 909\u2013919. https:\/\/doi.org\/10.1007\/s00432-019-02856-9 (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"16","key":"80579_CR10","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/0008-5472.Can-22-3645","volume":"83","author":"D Rohila","year":"2023","unstructured":"Rohila, D. et al. Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma. Cancer Res. 83 (16), 2675\u20132689. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-3645 (2023).","journal-title":"Cancer Res."},{"key":"80579_CR11","doi-asserted-by":"publisher","first-page":"110079","DOI":"10.1016\/j.cellsig.2021.110079","volume":"86","author":"R Boudria","year":"2021","unstructured":"Boudria, R. et al. Regulatory interplay between Vav1, Syk and \u03b2-catenin occurs in lung cancer cells. Cell Signal 86, 110079. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110079 (2021).","journal-title":"Cell Signal"},{"issue":"7381","key":"80579_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature10733","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481  (7381), 329\u2013334. https:\/\/doi.org\/10.1038\/nature10733 (2012).","journal-title":"Nature"},{"issue":"21","key":"80579_CR13","doi-asserted-by":"publisher","first-page":"12659","DOI":"10.1074\/jbc.270.21.12659","volume":"270","author":"RB Rowley","year":"1995","unstructured":"Rowley, R. B., Bolen, J. B. & Fargnoli, J. Molecular cloning of rodent p72Syk. Evidence of alternative mRNA splicing. J. Biol. Chem. 270 (21), 12659\u201312664. https:\/\/doi.org\/10.1074\/jbc.270.21.12659 (1995).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"80579_CR14","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1093\/emboj\/17.9.2584","volume":"17","author":"S Latour","year":"1998","unstructured":"Latour, S., Zhang, J., Siraganian, R. P. & Veillette, A. A unique insert in the linker domain of Syk is necessary for its function in immunoreceptor signalling. Embo J. 17 (9), 2584\u20132595. https:\/\/doi.org\/10.1093\/emboj\/17.9.2584 (1998).","journal-title":"Embo J."},{"issue":"15","key":"80579_CR15","first-page":"4724","volume":"63","author":"L Wang","year":"2003","unstructured":"Wang, L. et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 63 (15), 4724\u20134730 (2003).","journal-title":"Cancer Res."},{"issue":"9","key":"80579_CR16","doi-asserted-by":"publisher","first-page":"e0274390","DOI":"10.1371\/journal.pone.0274390","volume":"17","author":"V Denis","year":"2022","unstructured":"Denis, V. et al. Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells. PLoS ONE 17 (9), e0274390. https:\/\/doi.org\/10.1371\/journal.pone.0274390 (2022).","journal-title":"PLoS ONE"},{"issue":"6","key":"80579_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/0008-5472.Can-13-2104","volume":"74","author":"J Hong","year":"2014","unstructured":"Hong, J. et al. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res. 74 (6), 1845\u20131856. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-2104 (2014).","journal-title":"Cancer Res."},{"issue":"3","key":"80579_CR18","doi-asserted-by":"publisher","first-page":"L497","DOI":"10.1152\/ajplung.00246.2004","volume":"288","author":"M Ulanova","year":"2005","unstructured":"Ulanova, M. et al. Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 288 (3), L497-507. https:\/\/doi.org\/10.1152\/ajplung.00246.2004 (2005).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"9","key":"80579_CR19","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/mcb.26.9.3478-3491.2006","volume":"26","author":"F Zhou","year":"2006","unstructured":"Zhou, F., Hu, J., Ma, H., Harrison, M. L. & Geahlen, R. L. Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase. Mol. Cell Biol. 26 (9), 3478\u20133491. https:\/\/doi.org\/10.1128\/mcb.26.9.3478-3491.2006 (2006).","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"80579_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2005.05.022","volume":"236","author":"H Nakashima","year":"2006","unstructured":"Nakashima, H. et al. Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett. 236 (1), 89\u201394. https:\/\/doi.org\/10.1016\/j.canlet.2005.05.022 (2006).","journal-title":"Cancer Lett."},{"issue":"5","key":"80579_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00404-010-1546-6","volume":"283","author":"S Zhao","year":"2011","unstructured":"Zhao, S., Sun, G., Tony, P. W., Ma, D. & Zhao, C. Expression and methylation status of the Syk gene in cervical carcinoma. Arch. Gynecol. Obstet. 283 (5), 1113\u20131119. https:\/\/doi.org\/10.1007\/s00404-010-1546-6 (2011).","journal-title":"Arch. Gynecol. Obstet."},{"issue":"7","key":"80579_CR22","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/igc.0000000000000474","volume":"25","author":"E Jiang","year":"2015","unstructured":"Jiang, E. et al. Dehydrocostus lactone inhibits proliferation, antiapoptosis, and invasion of cervical cancer cells through PI3K\/Akt signaling pathway. Int. J. Gynecol. Cancer 25 (7), 1179\u20131186. https:\/\/doi.org\/10.1097\/igc.0000000000000474 (2015).","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"80579_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3892\/etm.2023.11845","volume":"25","author":"X Yang","year":"2023","unstructured":"Yang, X. & Zhu, W. ERBB3 mediates the PI3K\/AKT\/mTOR pathway to alter the epithelial-mesenchymal transition in cervical cancer and predict immunity filtration outcome. Exp. Ther. Med. 25 (4), 146. https:\/\/doi.org\/10.3892\/etm.2023.11845 (2023).","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"80579_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12885-022-09386-7","volume":"22","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. TIM-1 promotes proliferation and metastasis, and inhibits apoptosis, in cervical cancer through the PI3K\/AKT\/p53 pathway. BMC Cancer 22 (1), 370. https:\/\/doi.org\/10.1186\/s12885-022-09386-7 (2022).","journal-title":"BMC Cancer"},{"issue":"6","key":"80579_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cbf.3547","volume":"38","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Liu, S. & Zhu, Y. A-kinase-interacting protein 1 promotes EMT and metastasis via PI3K\/Akt\/IKK\u03b2 pathway in cervical cancer. Cell Biochem. Funct. 38 (6), 782\u2013791. https:\/\/doi.org\/10.1002\/cbf.3547 (2020).","journal-title":"Cell Biochem. Funct."},{"key":"80579_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejogrb.2020.02.014","volume":"247","author":"S Asthana","year":"2020","unstructured":"Asthana, S., Busa, V. & Labani, S. Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 247, 163\u2013175. https:\/\/doi.org\/10.1016\/j.ejogrb.2020.02.014 (2020).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"80579_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbamcr.2014.10.022","volume":"1853","author":"MO Krisenko","year":"2015","unstructured":"Krisenko, M. O. & Geahlen, R. L. Calling in SYK: SYK\u2019s dual role as a tumor promoter and tumor suppressor in cancer. Biochim. Biophys. Acta 1853 (1), 254\u2013263. https:\/\/doi.org\/10.1016\/j.bbamcr.2014.10.022 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"80579_CR28","doi-asserted-by":"publisher","first-page":"104529","DOI":"10.1016\/j.oraloncology.2019.104529","volume":"101","author":"M Black","year":"2020","unstructured":"Black, M. et al. Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer. Oral Oncol. 101, 104529. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104529 (2020).","journal-title":"Oral Oncol."},{"key":"80579_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbrc.2021.07.069","volume":"572","author":"T Wang","year":"2021","unstructured":"Wang, T., Xu, Y., Liu, X., Zeng, Y. & Liu, L. miR-96\u20135p is the tumor suppressor in osteosarcoma via targeting SYK. Biochem. Biophys. Res. Commun. 572, 49\u201356. https:\/\/doi.org\/10.1016\/j.bbrc.2021.07.069 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"80579_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005113","author":"A Aguirre-Ducler","year":"2022","unstructured":"Aguirre-Ducler, A. et al. Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-\u03b1 dependent signaling. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-005113 (2022).","journal-title":"J. Immunother. Cancer"},{"issue":"9\u201310","key":"80579_CR31","first-page":"407","volume":"56","author":"L Ma","year":"2010","unstructured":"Ma, L. et al. The relationship between methylation of the Syk gene in the promoter region and the genesis of lung cancer. Clin. Lab. 56 (9\u201310), 407\u2013416 (2010).","journal-title":"Clin. Lab."},{"issue":"22","key":"80579_CR32","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1158\/1078-0432.Ccr-06-0921","volume":"12","author":"Y Yuan","year":"2006","unstructured":"Yuan, Y. et al. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin. Cancer Res. 12 (22), 6687\u20136695. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0921 (2006).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"80579_CR33","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3892\/ol.2016.4858","volume":"12","author":"B Ni","year":"2016","unstructured":"Ni, B. et al. Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression. Oncol. Lett. 12 (3), 1737\u20131744. https:\/\/doi.org\/10.3892\/ol.2016.4858 (2016).","journal-title":"Oncol. Lett."},{"issue":"22","key":"80579_CR34","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1111\/febs.14665","volume":"285","author":"D Gao","year":"2018","unstructured":"Gao, D. et al. Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells. Febs J. 285 (22), 4229\u20134245. https:\/\/doi.org\/10.1111\/febs.14665 (2018).","journal-title":"Febs J."},{"issue":"9","key":"80579_CR35","doi-asserted-by":"publisher","first-page":"e0185607","DOI":"10.1371\/journal.pone.0185607","volume":"12","author":"RRJ Coebergh van den Braak","year":"2017","unstructured":"Coebergh van den Braak, R. R. J. et al. High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE 12 (9), e0185607. https:\/\/doi.org\/10.1371\/journal.pone.0185607 (2017).","journal-title":"PLoS ONE"},{"issue":"6","key":"80579_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nsmb.2040","volume":"18","author":"P Prinos","year":"2011","unstructured":"Prinos, P. et al. Alternative splicing of SYK regulates mitosis and cell survival. Nat. Struct. Mol. Biol. 18 (6), 673\u2013679. https:\/\/doi.org\/10.1038\/nsmb.2040 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"80579_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/neuonc\/noy008","volume":"20","author":"G Moncayo","year":"2018","unstructured":"Moncayo, G. et al. SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. Neuro Oncol. 20 (5), 621\u2013631. https:\/\/doi.org\/10.1093\/neuonc\/noy008 (2018).","journal-title":"Neuro Oncol."},{"issue":"5","key":"80579_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1084\/jem.20181827","volume":"216","author":"NM Aiello","year":"2019","unstructured":"Aiello, N. M. & Kang, Y. Context-dependent EMT programs in cancer metastasis. J. Exp. Med. 216 (5), 1016\u20131026. https:\/\/doi.org\/10.1084\/jem.20181827 (2019).","journal-title":"J. Exp. Med."},{"key":"80579_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102050118","author":"AP Deshmukh","year":"2021","unstructured":"Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl. Acad. Sci. U. S. A. https:\/\/doi.org\/10.1073\/pnas.2102050118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"80579_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","volume":"165","author":"M Karimi Roshan","year":"2019","unstructured":"Karimi Roshan, M. et al. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie 165, 229\u2013234. https:\/\/doi.org\/10.1016\/j.biochi.2019.08.003 (2019).","journal-title":"Biochimie"},{"issue":"1","key":"80579_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bbcan.2014.09.008","volume":"1855","author":"SA Danielsen","year":"2015","unstructured":"Danielsen, S. A. et al. Portrait of the PI3K\/AKT pathway in colorectal cancer. Biochim. Biophys. Acta 1855 (1), 104\u2013121. https:\/\/doi.org\/10.1016\/j.bbcan.2014.09.008 (2015).","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"80579_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12079-022-00702-1","volume":"17","author":"M Hashemi","year":"2023","unstructured":"Hashemi, M. et al. Targeting PI3K\/Akt signaling in prostate cancer therapy. J. Cell Commun. Signal 17 (3), 423\u2013443. https:\/\/doi.org\/10.1007\/s12079-022-00702-1 (2023).","journal-title":"J. Cell Commun. Signal"},{"key":"80579_CR43","doi-asserted-by":"publisher","first-page":"103749","DOI":"10.1016\/j.critrevonc.2022.103749","volume":"176","author":"M Mortazavi","year":"2022","unstructured":"Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E. & Firuzi, O. Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer. Crit. Rev. Oncol. Hematol. 176, 103749. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103749 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"80579_CR44","doi-asserted-by":"publisher","first-page":"154852","DOI":"10.1016\/j.prp.2023.154852","volume":"251","author":"WH Almalki","year":"2023","unstructured":"Almalki, W. H. Beyond the genome: lncRNAs as regulators of the PI3K\/AKT pathway in lung cancer. Pathol. Res. Pract. 251, 154852. https:\/\/doi.org\/10.1016\/j.prp.2023.154852 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"80579_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071685","author":"M Sabbah","year":"2021","unstructured":"Sabbah, M. et al. RTK inhibitors in melanoma: From bench to bedside. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13071685 (2021).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"80579_CR46","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1515\/med-2022-0453","volume":"17","author":"L Huang","year":"2022","unstructured":"Huang, L. et al. Tollip promotes hepatocellular carcinoma progression via PI3K\/AKT pathway. Open Med. (Wars) 17 (1), 626\u2013637. https:\/\/doi.org\/10.1515\/med-2022-0453 (2022).","journal-title":"Open Med. (Wars)"},{"issue":"11","key":"80579_CR47","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1139\/cjpp-2020-0503","volume":"99","author":"QL Zhang","year":"2021","unstructured":"Zhang, Q. L. et al. The protein tyrosine kinase inhibitor genistein suppresses hypoxia-induced atrial natriuretic peptide secretion mediated by the PI3K\/Akt-HIF-1\u03b1 pathway in isolated beating rat atria. Can. J. Physiol. Pharmacol. 99 (11), 1184\u20131190. https:\/\/doi.org\/10.1139\/cjpp-2020-0503 (2021).","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"3","key":"80579_CR48","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/jcb.21678","volume":"104","author":"R Agrawal","year":"2008","unstructured":"Agrawal, R., Carpino, N. & Tsygankov, A. TULA proteins regulate activity of the protein tyrosine kinase Syk. J. Cell Biochem. 104 (3), 953\u2013964. https:\/\/doi.org\/10.1002\/jcb.21678 (2008).","journal-title":"J. Cell Biochem."},{"issue":"4","key":"80579_CR49","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.7150\/jca.91360","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. AQP3 promotes the invasion and metastasis in cervical cancer by regulating NOX4-derived H(2)O(2) activation of Syk\/PI3K\/Akt signaling axis. J. Cancer 15 (4), 1124\u20131137. https:\/\/doi.org\/10.7150\/jca.91360 (2024).","journal-title":"J. Cancer"},{"issue":"1","key":"80579_CR50","doi-asserted-by":"publisher","first-page":"2369766","DOI":"10.1080\/09537104.2024.2369766","volume":"35","author":"C Dangelmaier","year":"2024","unstructured":"Dangelmaier, C. et al. Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets. Platelets 35 (1), 2369766. https:\/\/doi.org\/10.1080\/09537104.2024.2369766 (2024).","journal-title":"Platelets"},{"issue":"10","key":"80579_CR51","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.molcel.2021.03.043","volume":"81","author":"T Sadras","year":"2021","unstructured":"Sadras, T. et al. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Mol. Cell 81 (10), 2094\u2013111.e9. https:\/\/doi.org\/10.1016\/j.molcel.2021.03.043 (2021).","journal-title":"Mol. Cell"},{"issue":"5","key":"80579_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jmv.25381","volume":"91","author":"R Incrocci","year":"2019","unstructured":"Incrocci, R. et al. Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-\u03baB in B-cell lymphomas to increase MIP-1\u03b1 production. J. Med. Virol. 91 (5), 845\u2013855. https:\/\/doi.org\/10.1002\/jmv.25381 (2019).","journal-title":"J. Med. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80579-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T16:03:15Z","timestamp":1732377795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80579-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80579"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80579-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All clinical experiments in this study were approved by the Ethics Committee of Xinjiang Medical University Affiliated Cancer Hospital. All included patients have signed informed consent forms.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"29080"}}